Farmers & Merchants Bancorp, Inc. reported a 30.3% increase in net income to $11.5 million for Q3 2026, driven by improved net interest margin and strong asset quality. The company also raised its regular dividend by 5.5% and declared a special dividend, reflecting confidence in sustained profitability and growth. Deposits and loans grew moderately, with continued focus on operational efficiency and capital returns. Management expects positive momentum to continue into 2027 amid a favorable interest rate environment.
Farmers & Merchants Bancorp, Inc. reported a 30.3% rise in net income for Q3 2026, signaling strong financial performance. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 23, 2026 03:11 WIB: out of 142 priced US Financials stocks, 81 rose and 59 fell. Notable movers include BMNR at USD 22.43 with a 6.39% decline and 100% sell order activity, RKT at USD 11.79 with a 6.08% gain and 100% buy order activity, and VLY at USD 13.79 with a 5.91% gain and 100% buy order activity.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Lycia Therapeutics, a biotech company developing therapies targeting disease-causing proteins, priced its upsized initial public offering at $18 per share, raising approximately $317.5 million before expenses. The company plans to use the funds to ad...
